Detailed Information Sample Clauses

Detailed Information. Plan details shall be maintained in the Human Resources Department and made available to employees upon request.
Sample 1Sample 2Sample 3See All (10)
AutoNDA by SimpleDocs
Detailed Information. Detailed information on our arrangements established for the safeguard of clients’ assets is provided through the document “Client Assets Protection”.
Sample 1Sample 2Sample 3See All (5)
Detailed Information. The detailed portion of the report shall contain the following: • A matrix and explanation of all operating scenarios evaluated. • A list and explanation of assumptions made.
Sample 1Sample 2Sample 3
Detailed Information. The following is more detailed information about this study in addition to the information listed above. Who can I talk to? If you have questions, concerns, or complaints, or think the research has hurt you, talk to the research team at 000-000-0000 (day) or 000-000-0000 (24 hours); Ask for Xx. Xxxxxxxx This research has been reviewed and approved by the Ascension St. Xxxx Hospital Institutional Review Board (“IRB”). You may talk to them at (000) 000-0000 if: • Your questions, concerns, or complaints are not being answered by the research team. • You cannot reach the research team. • You want to talk to someone besides the research team. • You have questions about your rights as a research subject. • You want to get information or provide input about this research. How many people will be studied? We expect about 100 people here will be in this research study out of 200 people in the entire study nationwide. What happens if I say yes, I want to be in this research? • A nasal swab will be collected for the COVID test your doctor ordered. • A second nasal swab will then be collected. • The first nasal swab will be used for the COVID test your doctor ordered and results will be provided to your doctor. • These swabs will be assigned a unique number that will be linked to your first COVID test swab. • The second nasal swab will be used for a different COVID test. • The research team will compare the results of the first COVID test to the second COVID test. • If the new test results are as good as the first test results, the new test can may be recommended to use for testing COVID patients in the future. What are my responsibilities if I take part in this research? If you take part in this research, you will be responsible for only the time spent collecting the swabs and signing the paperwork. What happens if I say yes, but I change my mind later? You can leave the research at any time it will not be held against you. There are no consequences for leaving the study. If you decide to leave the research, contact the investigator so that the investigator can remove your swab sample from the study. Is there any way being in this study could be bad for me? (Detailed Risks) You may experience some discomfort after collection of the swab from your nose. There is also a risk of loss of confidentiality. We will assign your swabs a study ID and you will only be identified by the study ID. You and your insurance company will be charged for the health care services that yo...
Sample 1

Related to Detailed Information

  • Included Information For purposes of this Agreement, the term “Confidential Information” means all confidential and proprietary information of a party, including but not limited to (i) financial information, (ii) business and marketing plans, (iii) the names of employees and owners, (iv) the names and other personally-identifiable information of users of the third-party provided online fundraising platform, (v) security codes, and (vi) all documentation provided by Client or Investor.

  • Background Information (A) The Adviser has entered into an Investment Adviser's Agreement with the Fund ("Investment Adviser's Agreement"). Pursuant to the Investment Adviser's Agreement, the Adviser has agreed to render investment advisory and certain other management services to all of the funds of the Fund, and the Fund has agreed to employ the Adviser to render such services and to pay to the Adviser certain fees therefore. The Investment Adviser's Agreement recognizes that the Adviser may enter into agreements with other investment advisers who will serve as fund managers to the funds.

  • Furnish Specified Information It will deliver to the other party or, in certain cases under subparagraph (iii) below, to such government or taxing authority as the other party reasonably directs:--

  • De-identified Information De-identified Information may be used by the Operator only for the purposes of development, product improvement, to demonstrate or market product effectiveness, or research as any other member of the public or party would be able to use de-identified data pursuant to 34 CFR 99.31(b). Operator agrees not to attempt to re-identify De-identified Information and not to transfer De-identified Information to any party unless (a) that party agrees in writing not to attempt re- identification, and (b) prior written notice has been given to LEA who has provided prior written consent for such transfer. Operator shall not copy, reproduce or transmit any De-identified Information or other Data obtained under the Service Agreement except as necessary to fulfill the Service Agreement.

  • Requested Information with reasonable promptness, such other data and information relating to the business, operations, affairs, financial condition, assets or properties of the Company or any of its Subsidiaries or relating to the ability of the Company to perform its obligations hereunder and under the Notes as from time to time may be reasonably requested by any such holder of Notes.

  • Information The Buyer and its advisors, if any, have been, and for so long as the Note remain outstanding will continue to be, furnished with all materials relating to the business, finances and operations of the Company and materials relating to the offer and sale of the Securities which have been requested by the Buyer or its advisors. The Buyer and its advisors, if any, have been, and for so long as the Note remain outstanding will continue to be, afforded the opportunity to ask questions of the Company. Notwithstanding the foregoing, the Company has not disclosed to the Buyer any material nonpublic information and will not disclose such information unless such information is disclosed to the public prior to or promptly following such disclosure to the Buyer. Neither such inquiries nor any other due diligence investigation conducted by Buyer or any of its advisors or representatives shall modify, amend or affect Buyer’s right to rely on the Company’s representations and warranties contained in Section 3 below. The Buyer understands that its investment in the Securities involves a significant degree of risk. The Buyer is not aware of any facts that may constitute a breach of any of the Company's representations and warranties made herein.

  • Classified Information In no event shall any of the Copyright Collateral, Patent Collateral or Trademark Collateral include any Copyright, Patent or Trademark, any application for a Copyright, Patent or Trademark, or any license or right under any Copyright, Patent or Trademark that is “classified” for reasons of national security or foreign policy under applicable laws or with respect to which Pledgor is not entitled to pledge, sublicense or assign pursuant to its terms or applicable law or regulation.

  • Excluded Information For purposes of this Agreement, the term “confidential and proprietary information” shall not include (i) information already known or independently developed by the recipient without the use of any confidential and proprietary information, or (ii) information known to the public through no wrongful act of the recipient.

  • Updating information You must tell us promptly if information you have provided to us changes, including if your billing address changes or if your use of energy changes (for example, if you start running a business at the premises).

  • Identifying Information Issuer and Broker acknowledge that a portion of the identifying information set forth on Exhibit A is being requested by NCPS in connection with the USA Patriot Act, Pub.L.107-56 (the “Act”). To help the government fight the funding of terrorism and money laundering activities, Federal law requires all financial institutions to obtain, verify, and record information that identifies each person who opens an account. For a non-individual person such as a business entity, a charity, a Trust, or other legal entity, we ask for documentation to verify its formation and existence as a legal entity. We may also ask to see financial statements, licenses, identification and authorization documents from individuals claiming authority to represent the entity or other relevant documentation.

Time is Money Join Law Insider Premium to draft better contracts faster.